Exploristics surges ahead with £1m investment

15 Apr 2019

The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.

Data analysis and clinical trial software specialist, Exploristics, has announced a £1m government innovation loan from Innovate UK and the appointment of Chris Molloy as its non-executive chairman following a period of significant growth.

Exploristics surges ahead with £1m investment

The company has seen yearly turnover reach a new milestone of £1m thanks to the success of its groundbreaking cloud-based data analytics platform for clinical trial design, KERUS Cloud.

Providing a virtual environment for optimising clinical study design and data analysis, KERUS Cloud is a unique simulation software tool supported by the processing power of cloud computing that removes barriers to accessing cutting-edge clinical trial planning.

It is currently the only software available that can simulate trials with multiple correlated outcomes allowing it to untangle the complex relationships between the many biological factors that can influence a study’s outcome.

The KERUS Cloud platform’s potential to transform the speed and efficiency of bringing new medicines to market has been recognised by government bodies and Exploristics has recently been granted a £1m Innovate UK loan to develop the platform’s capabilities further by integrating it into an intelligent software ecosystem.

The KERUS Cloud Ecosystem will enable access to diverse clinical data sources, creating an unparalleled knowledge base for selected therapeutic areas and development programs. This will inform and generate the most accurate study simulations available to date, supporting the complex trial planning needed in the development of new therapeutic interventions.

At this pivotal time for the company, Chris Molloy’s appointment will bring extensive knowledge of the life sciences sector to the table as well as nearly 30 years of international executive and board experience. He is also currently the CEO of Medicines Discovery Catapult.

As the new non-executive chairman at Exploristics, Chris’ role will be to oversee its continued growth from a small company providing specialist statistical consultancy for the life science industry to a world leader in innovative analytics software for clinical R&D and in silico clinical trial modelling, simulation and design.

Chris said: “It’s an exciting time to be joining Exploristics as there is real need for optimised, data-driven clinical trial design, particularly as biopharmaceutical companies face the challenges presented by emerging research areas such as precision medicine.

“KERUS Cloud really addresses this need and I believe it will have a truly transformative effect on the industry. I look forward to working with the team to achieve this and drive forward the company’s growth.”

Dr Aiden Flynn, CEO of Exploristics, who founded the business in 2009, said: “It’s a pleasure to welcome Chris to the team at such a key moment for the business and his leadership experience and industry knowledge will be central to supporting our growth strategy.

“Our next generation trial design software seeks to improve the quality of global clinical research and ultimately ensure that patients benefit from new drug therapies as quickly and efficiently as possible.

“This latest funding brings us another step closer to achieving that goal and help to revolutionise clinical trials across the globe.”

Over the coming months, Exploristics will be attending several events to promote KERUS Cloud including BIO Europe Spring in Vienna and the CMO Summit in Boston.

Read More

Related news

Catalent to acquire gene therapy leader Paragon Bioservices

Catalent to acquire gene therapy leader Paragon Bioservices

16 Apr 2019

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.

Read more 
Catalent celebrates opening of second Shanghai facility

Catalent celebrates opening of second Shanghai facility

14 Apr 2019

Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.

Read more 
Colorcon expands functional film coatings through the CR Alliance with DuPont

Colorcon expands functional film coatings through the CR Alliance with DuPont

15 Apr 2019

The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

12 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more 
TTP spin-out to commercialise next-generation cell-sorting technology

TTP spin-out to commercialise next-generation cell-sorting technology

7 Apr 2019

Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more